Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA reclassification proposed rule

This article was originally published in The Gray Sheet

Executive Summary

Agency is extending comment period for three of 38 pre-1976 devices proposed for reclassification from Class III to Class II. Comments must be submitted 90 days from Nov. 22. Specifically, the action relates to in-dwelling blood carbon dioxide partial pressure analyzers, blood hydrogen ion concentration analyzers, and blood oxygen partial pressure analyzers. Original mass reclassification was published in March 15, 1999 issue of Federal Register (1"The Gray Sheet" March 22, 1999, p. 10). Guidance for premarket 510(k) notification submissions for indwelling blood gas analyzers is released in the Nov. 22 Federal Register. Comments are due by Feb. 20

Latest Headlines
See All
UsernamePublicRestriction

Register

MT014171

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel